Suppression of experimental autoimmune myasthenia gravis by combination therapy: Pentoxifylline as a steroid-sparing agent

Keyphrases

• Experimental Autoimmune Myasthenia Gravis 100%
• Steroid-sparing 100%
• Pentoxifylline 100%
• Combination Therapy 100%
• Myasthenia Gravis 66%
• Experimental Autoimmune 66%
• Suppression Effect 66%
• Methylprednisolone 66%
• Adverse Effects 33%
• Cellular Response 33%
• Therapeutic Potential 33%
• MRNA Level 33%
• Acetylcholine Receptor (AChR) 33%
• Humoral Response 33%
• Interleukin-10 33%
• Th1 Cytokines 33%
• Lymph Node Cells 33%
• Corticosteroids 33%
• Combined Treatment 33%
• Continuous Treatment 33%
• Cathepsin L 33%
• Suboptimal Dose 33%
• Phosphodiesterase-4 (PDE4) 33%
• Phosphodiesterase Inhibitors 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Experimental Autoimmune Myasthenia Gravis 100%
• Pentoxifylline 100%
• Combination Therapy 100%
• Myasthenia gravis 66%
• Methylprednisolone 66%
• Adverse Event 33%
• Cytokine 33%
• Phosphodiesterase Inhibitor 33%
• Phosphodiesterase IV 33%
• Cathepsin 33%
• Methylprednisolone Sodium Succinate 33%

Immunology and Microbiology

• Experimental Autoimmune Myasthenia Gravis 100%
• Pentoxifylline 100%
• Myasthenia gravis 66%
• Methylprednisolone 66%
• Cytokine 33%
• Lymph Node Cell 33%
• Low Drug Dose 33%
• mRNA Expression Level 33%
• Methylprednisolone Sodium Succinate 33%